#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-6	Effect	_
1-2	7-9	of	_
1-3	10-19	rs1344706	_
1-4	20-22	in	_
1-5	23-26	the	_
1-6	27-34	ZNF804A	_
1-7	35-39	gene	_
1-8	40-42	on	_
1-9	43-46	the	_
1-10	47-52	brain	_
1-11	53-60	network	_
1-12	61-68	ZNF804A	_
1-13	69-78	rs1344706	_
1-14	79-80	(	_
1-15	81-84	A/C	_
1-16	85-86	)	_
1-17	87-90	was	_
1-18	91-94	the	_
1-19	95-100	first	_
1-20	101-104	SNP	_
1-21	105-109	that	_
1-22	110-117	reached	_
1-23	118-129	genome-wide	_
1-24	130-142	significance	_
1-25	143-146	for	_
1-26	147-160	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-27	161-162	.	_

2-1	163-169	Recent	_
2-2	170-177	studies	_
2-3	178-182	have	_
2-4	183-189	linked	_
2-5	190-199	rs1344706	_
2-6	200-202	to	_
2-7	203-213	functional	_
2-8	214-226	connectivity	_
2-9	227-232	among	_
2-10	233-241	specific	_
2-11	242-247	brain	_
2-12	248-255	regions	_
2-13	256-257	.	_

3-1	258-265	However	_
3-2	266-267	,	_
3-3	268-270	no	_
3-4	271-276	study	_
3-5	277-281	thus	_
3-6	282-285	far	_
3-7	286-289	has	_
3-8	290-298	examined	_
3-9	299-302	the	_
3-10	303-307	role	_
3-11	308-310	of	_
3-12	311-315	this	_
3-13	316-319	SNP	_
3-14	320-322	in	_
3-15	323-326	the	_
3-16	327-333	entire	_
3-17	334-344	functional	_
3-18	345-355	connectome	_
3-19	356-357	.	_

4-1	358-360	In	_
4-2	361-365	this	_
4-3	366-371	study	_
4-4	372-373	,	_
4-5	374-376	we	_
4-6	377-381	used	_
4-7	382-388	degree	_
4-8	389-399	centrality	_
4-9	400-402	to	_
4-10	403-407	test	_
4-11	408-411	the	_
4-12	412-416	role	_
4-13	417-419	of	_
4-14	420-429	rs1344706	_
4-15	430-432	in	_
4-16	433-436	the	_
4-17	437-448	whole-brain	_
4-18	449-459	voxel-wise	_
4-19	460-470	functional	_
4-20	471-481	connectome	_
4-21	482-488	during	_
4-22	489-492	the	_
4-23	493-500	resting	_
4-24	501-506	state	_
4-25	507-508	.	_

5-1	509-511	52	_
5-2	512-525	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-3	526-534	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-4	535-538	and	_
5-5	539-542	128	_
5-6	543-550	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-7	551-559	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-8	560-564	were	_
5-9	565-573	included	_
5-10	574-576	in	_
5-11	577-580	the	_
5-12	581-586	final	_
5-13	587-595	analysis	_
5-14	596-597	.	_

6-1	598-600	In	_
6-2	601-604	our	_
6-3	605-616	whole-brain	_
6-4	617-625	analysis	_
6-5	626-627	,	_
6-6	628-630	we	_
6-7	631-636	found	_
6-8	637-638	a	_
6-9	639-650	significant	_
6-10	651-662	interaction	_
6-11	663-669	effect	_
6-12	670-672	of	_
6-13	673-681	genotype	_
6-14	682-683	×	_
6-15	684-693	diagnosis	_
6-16	694-696	at	_
6-17	697-700	the	_
6-18	701-710	precuneus	_
6-19	711-712	(	_
6-20	713-716	PCU	_
6-21	717-718	)	_
6-22	719-720	(	_
6-23	721-728	cluster	_
6-24	729-733	size	_
6-25	734-735	=	_
6-26	736-738	52	_
6-27	739-745	voxels	_
6-28	746-747	,	_
6-29	748-752	peak	_
6-30	753-758	voxel	_
6-31	759-762	MNI	_
6-32	763-774	coordinates	_
6-33	775-776	:	_
6-34	777-778	x	_
6-35	779-780	=	_
6-36	781-782	9	_
6-37	783-784	,	_
6-38	785-786	y	_
6-39	787-788	=	_
6-40	789-790	−	_
6-41	791-793	69	_
6-42	794-795	,	_
6-43	796-797	z	_
6-44	798-799	=	_
6-45	800-802	63	_
6-46	803-804	,	_
6-47	805-806	F	_
6-48	807-808	=	_
6-49	809-814	32.57	_
6-50	815-816	,	_
6-51	817-820	FWE	_
6-52	821-830	corrected	_
6-53	831-832	P	_
6-54	833-834	<	_
6-55	835-840	0.001	_
6-56	841-842	)	_
6-57	843-844	.	_

7-1	845-849	When	_
7-2	850-852	we	_
7-3	853-863	subdivided	_
7-4	864-867	the	_
7-5	868-874	degree	_
7-6	875-885	centrality	_
7-7	886-893	network	_
7-8	894-903	according	_
7-9	904-906	to	_
7-10	907-917	anatomical	_
7-11	918-926	distance	_
7-12	927-928	,	_
7-13	929-932	the	_
7-14	933-944	whole-brain	_
7-15	945-953	analysis	_
7-16	954-958	also	_
7-17	959-964	found	_
7-18	965-966	a	_
7-19	967-978	significant	_
7-20	979-990	interaction	_
7-21	991-997	effect	_
7-22	998-1000	of	_
7-23	1001-1009	genotype	_
7-24	1010-1011	×	_
7-25	1012-1021	diagnosis	_
7-26	1022-1024	at	_
7-27	1025-1028	the	_
7-28	1029-1032	PCU	_
7-29	1033-1037	with	_
7-30	1038-1041	the	_
7-31	1042-1046	same	_
7-32	1047-1051	peak	_
7-33	1052-1054	in	_
7-34	1055-1058	the	_
7-35	1059-1070	short-range	_
7-36	1071-1077	degree	_
7-37	1078-1088	centrality	_
7-38	1089-1096	network	_
7-39	1097-1098	(	_
7-40	1099-1106	cluster	_
7-41	1107-1111	size	_
7-42	1112-1113	=	_
7-43	1114-1116	72	_
7-44	1117-1123	voxels	_
7-45	1124-1125	,	_
7-46	1126-1127	F	_
7-47	1128-1129	=	_
7-48	1130-1135	37.29	_
7-49	1136-1137	,	_
7-50	1138-1141	FWE	_
7-51	1142-1151	corrected	_
7-52	1152-1153	P	_
7-53	1154-1155	<	_
7-54	1156-1161	0.001	_
7-55	1162-1163	)	_
7-56	1164-1165	.	_

8-1	1166-1168	No	_
8-2	1169-1180	significant	_
8-3	1181-1187	result	_
8-4	1188-1191	was	_
8-5	1192-1197	found	_
8-6	1198-1200	in	_
8-7	1201-1204	the	_
8-8	1205-1215	long-range	_
8-9	1216-1222	degree	_
8-10	1223-1233	centrality	_
8-11	1234-1241	network	_
8-12	1242-1243	.	_

9-1	1244-1247	Our	_
9-2	1248-1255	results	_
9-3	1256-1266	elucidated	_
9-4	1267-1270	the	_
9-5	1271-1283	contribution	_
9-6	1284-1286	of	_
9-7	1287-1296	rs1344706	_
9-8	1297-1299	to	_
9-9	1300-1310	functional	_
9-10	1311-1323	connectivity	_
9-11	1324-1330	within	_
9-12	1331-1334	the	_
9-13	1335-1340	brain	_
9-14	1341-1348	network	_
9-15	1349-1350	,	_
9-16	1351-1354	and	_
9-17	1355-1358	may	_
9-18	1359-1363	have	_
9-19	1364-1373	important	_
9-20	1374-1386	implications	_
9-21	1387-1390	for	_
9-22	1391-1394	our	_
9-23	1395-1408	understanding	_
9-24	1409-1411	of	_
9-25	1412-1416	this	_
9-26	1417-1421	risk	_
9-27	1422-1426	gene	_
9-28	1427-1429	's	_
9-29	1430-1434	role	_
9-30	1435-1437	in	_
9-31	1438-1448	functional	_
9-32	1449-1464	dysconnectivity	_
9-33	1465-1467	in	_
9-34	1468-1481	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-35	1482-1483	.	_

10-1	1484-1494	Highlights	_
10-2	1495-1499	This	_
10-3	1500-1505	study	_
10-4	1506-1509	was	_
10-5	1510-1513	the	_
10-6	1514-1519	first	_
10-7	1520-1522	to	_
10-8	1523-1529	report	_
10-9	1530-1533	the	_
10-10	1534-1540	effect	_
10-11	1541-1543	of	_
10-12	1544-1551	ZNF804A	_
10-13	1552-1561	rs1344706	_
10-14	1562-1564	on	_
10-15	1565-1568	the	_
10-16	1569-1577	property	_
10-17	1578-1580	of	_
10-18	1581-1584	the	_
10-19	1585-1596	whole-brain	_
10-20	1597-1604	network	_
10-21	1605-1606	.	_

11-1	1607-1609	We	_
11-2	1610-1615	found	_
11-3	1616-1617	a	_
11-4	1618-1629	significant	_
11-5	1630-1641	interaction	_
11-6	1642-1644	of	_
11-7	1645-1654	rs1344706	_
11-8	1655-1663	genotype	_
11-9	1664-1665	×	_
11-10	1666-1675	diagnosis	_
11-11	1676-1678	on	_
11-12	1679-1682	the	_
11-13	1683-1693	functional	_
11-14	1694-1706	connectivity	_
11-15	1707-1709	of	_
11-16	1710-1713	the	_
11-17	1714-1717	PCU	_
11-18	1718-1719	.	_

12-1	1720-1729	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1730-1733	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1734-1741	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	1742-1754	Participants	_
12-5	1755-1758	The	_
12-6	1759-1766	initial	_
12-7	1767-1773	sample	_
12-8	1774-1783	consisted	_
12-9	1784-1786	of	_
12-10	1787-1789	55	_
12-11	1790-1803	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-12	1804-1812	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-13	1813-1816	and	_
12-14	1817-1820	137	_
12-15	1821-1828	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-16	1829-1837	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-17	1838-1839	.	_

13-1	1840-1843	Due	_
13-2	1844-1846	to	_
13-3	1847-1852	their	_
13-4	1853-1862	excessive	_
13-5	1863-1867	head	_
13-6	1868-1874	motion	_
13-7	1875-1876	(	_
13-8	1877-1878	>	_
13-9	1879-1881	3°	_
13-10	1882-1884	or	_
13-11	1885-1886	3	_
13-12	1887-1889	mm	_
13-13	1890-1891	)	_
13-14	1892-1895	and	_
13-15	1896-1903	failure	_
13-16	1904-1906	of	_
13-17	1907-1919	registration	_
13-18	1920-1921	(	_
13-19	1922-1925	due	_
13-20	1926-1928	to	_
13-21	1929-1932	low	_
13-22	1933-1940	quality	_
13-23	1941-1943	of	_
13-24	1944-1946	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
13-25	1947-1953	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
13-26	1954-1955	)	_
13-27	1956-1957	,	_
13-28	1958-1959	3	_
13-29	1960-1968	patients	_
13-30	1969-1972	and	_
13-31	1973-1974	9	_
13-32	1975-1982	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-33	1983-1991	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-34	1992-1996	were	_
13-35	1997-2005	excluded	_
13-36	2006-2007	.	_

14-1	2008-2011	Due	_
14-2	2012-2014	to	_
14-3	2015-2018	the	_
14-4	2019-2024	small	_
14-5	2025-2031	number	_
14-6	2032-2034	of	_
14-7	2035-2038	the	_
14-8	2039-2051	minor-allele	_
14-9	2052-2063	homozygotes	_
14-10	2064-2065	(	_
14-11	2066-2068	10	_
14-12	2069-2077	patients	_
14-13	2078-2081	and	_
14-14	2082-2084	28	_
14-15	2085-2093	controls	_
14-16	2094-2095	)	_
14-17	2096-2097	,	_
14-18	2098-2100	we	_
14-19	2101-2109	combined	_
14-20	2110-2113	the	_
14-21	2114-2116	CC	_
14-22	2117-2125	genotype	_
14-23	2126-2130	with	_
14-24	2131-2134	the	_
14-25	2135-2137	CA	_
14-26	2138-2146	genotype	_
14-27	2147-2149	as	_
14-28	2150-2153	the	_
14-29	2154-2162	non-risk	_
14-30	2163-2169	allele	_
14-31	2170-2178	carriers	_
14-32	2179-2180	.	_

15-1	2181-2184	The	_
15-2	2185-2190	final	_
15-3	2191-2195	data	_
15-4	2196-2204	analysis	_
15-5	2205-2213	included	_
15-6	2214-2216	52	_
15-7	2217-2230	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-8	2231-2239	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-9	2240-2241	(	_
15-10	2242-2244	34	_
15-11	2245-2250	CA/CC	_
15-12	2251-2254	and	_
15-13	2255-2257	18	_
15-14	2258-2260	AA	_
15-15	2261-2262	)	_
15-16	2263-2266	and	_
15-17	2267-2270	128	_
15-18	2271-2278	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-19	2279-2287	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-20	2288-2289	(	_
15-21	2290-2292	96	_
15-22	2293-2298	CA/CC	_
15-23	2299-2302	and	_
15-24	2303-2305	32	_
15-25	2306-2308	AA	_
15-26	2309-2310	)	_
15-27	2311-2312	.	_

16-1	2313-2316	The	_
16-2	2317-2325	patients	_
16-3	2326-2330	were	_
16-4	2331-2340	recruited	_
16-5	2341-2345	from	_
16-6	2346-2349	the	_
16-7	2350-2360	inpatients	_
16-8	2361-2363	of	_
16-9	2364-2367	the	_
16-10	2368-2375	Beijing	_
16-11	2376-2382	Anding	_
16-12	2383-2391	Hospital	_
16-13	2392-2393	.	_

17-1	2394-2397	All	_
17-2	2398-2406	patients	_
17-3	2407-2416	fulfilled	_
17-4	2417-2420	the	_
17-5	2421-2427	DSM-IV	_
17-6	2428-2436	criteria	_
17-7	2437-2440	for	_
17-8	2441-2454	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-9	2455-2464	according	_
17-10	2465-2467	to	_
17-11	2468-2471	the	_
17-12	2472-2482	diagnostic	_
17-13	2483-2492	consensus	_
17-14	2493-2495	of	_
17-15	2496-2499	two	_
17-16	2500-2511	experienced	_
17-17	2512-2525	psychiatrists	_
17-18	2526-2531	based	_
17-19	2532-2534	on	_
17-20	2535-2545	structured	_
17-21	2546-2555	interview	_
17-22	2556-2557	(	_
17-23	2558-2562	SCID	_
17-24	2563-2564	)	_
17-25	2565-2566	.	_

18-1	2567-2570	The	_
18-2	2571-2579	positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-3	2580-2583	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-4	2584-2592	negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-5	2593-2601	syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-6	2602-2607	scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-7	2608-2609	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-8	2610-2615	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-9	2616-2617	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
18-10	2618-2621	was	_
18-11	2622-2626	used	_
18-12	2627-2629	to	_
18-13	2630-2636	assess	_
18-14	2637-2641	each	_
18-15	2642-2649	patient	_
18-16	2650-2652	's	_
18-17	2653-2661	positive	_
18-18	2662-2663	(	_
18-19	2664-2668	SAPS	_
18-20	2669-2670	)	_
18-21	2671-2674	and	_
18-22	2675-2683	negative	_
18-23	2684-2685	(	_
18-24	2686-2690	SANS	_
18-25	2691-2692	)	_
18-26	2693-2701	symptoms	_
18-27	2702-2703	.	_

19-1	2704-2707	The	_
19-2	2708-2712	mean	_
19-3	2713-2719	scores	_
19-4	2720-2722	of	_
19-5	2723-2726	the	_
19-6	2727-2731	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-7	2732-2735	and	_
19-8	2736-2740	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-9	2741-2744	are	_
19-10	2745-2750	shown	_
19-11	2751-2753	in	_
19-12	2754-2759	Table	_
19-13	2760-2761	1	_
19-14	2762-2763	.	_

20-1	2764-2767	All	_
20-2	2768-2776	patients	_
20-3	2777-2781	were	_
20-4	2782-2789	treated	_
20-5	2790-2794	with	_
20-6	2795-2801	stable	_
20-7	2802-2807	doses	_
20-8	2808-2810	of	_
20-9	2811-2819	atypical	_
20-10	2820-2834	antipsychotics	_
20-11	2835-2838	for	_
20-12	2839-2840	>	_
20-13	2841-2842	2	_
20-14	2843-2848	weeks	_
20-15	2849-2850	.	_

21-1	2851-2864	Antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
21-2	2865-2870	drugs	_
21-3	2871-2879	included	_
21-4	2880-2889	clozapine	_
21-5	2890-2891	(	_
21-6	2892-2893	5	_
21-7	2894-2902	patients	_
21-8	2903-2904	)	_
21-9	2905-2906	,	_
21-10	2907-2917	olanzapine	_
21-11	2918-2919	(	_
21-12	2920-2922	13	_
21-13	2923-2931	patients	_
21-14	2932-2933	)	_
21-15	2934-2935	,	_
21-16	2936-2947	risperidone	_
21-17	2948-2949	(	_
21-18	2950-2952	22	_
21-19	2953-2961	patients	_
21-20	2962-2963	)	_
21-21	2964-2965	,	_
21-22	2966-2978	aripiprazole	_
21-23	2979-2980	(	_
21-24	2981-2982	6	_
21-25	2983-2991	patients	_
21-26	2992-2993	)	_
21-27	2994-2995	,	_
21-28	2996-2999	and	_
21-29	3000-3011	haloperidol	_
21-30	3012-3013	(	_
21-31	3014-3015	6	_
21-32	3016-3024	patients	_
21-33	3025-3026	)	_
21-34	3027-3028	.	_

22-1	3029-3031	No	_
22-2	3032-3047	antidepressants	_
22-3	3048-3052	were	_
22-4	3053-3061	involved	_
22-5	3062-3063	.	_

23-1	3064-3072	Patients	_
23-2	3073-3077	took	_
23-3	3078-3083	2.5–5	_
23-4	3084-3086	mg	_
23-5	3087-3095	diazepam	_
23-6	3096-3108	occasionally	_
23-7	3109-3112	for	_
23-8	3113-3118	their	_
23-9	3119-3127	insomnia	_
23-10	3128-3129	.	_

24-1	3130-3137	However	_
24-2	3138-3139	,	_
24-3	3140-3148	patients	_
24-4	3149-3153	were	_
24-5	3154-3159	asked	_
24-6	3160-3163	not	_
24-7	3164-3166	to	_
24-8	3167-3171	take	_
24-9	3172-3180	diazepam	_
24-10	3181-3183	or	_
24-11	3184-3189	other	_
24-12	3190-3205	benzodiazepines	_
24-13	3206-3208	on	_
24-14	3209-3212	the	_
24-15	3213-3218	night	_
24-16	3219-3225	before	_
24-17	3226-3229	the	_
24-18	3230-3234	scan	_
24-19	3235-3236	.	_

25-1	3237-3239	If	_
25-2	3240-3244	they	_
25-3	3245-3248	did	_
25-4	3249-3250	,	_
25-5	3251-3256	their	_
25-6	3257-3269	appointments	_
25-7	3270-3273	for	_
25-8	3274-3278	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
25-9	3279-3284	scans	_
25-10	3285-3289	were	_
25-11	3290-3298	canceled	_
25-12	3299-3300	.	_

26-1	3301-3310	Exclusion	_
26-2	3311-3319	criteria	_
26-3	3320-3323	for	_
26-4	3324-3327	the	_
26-5	3328-3336	patients	_
26-6	3337-3345	included	_
26-7	3346-3347	a	_
26-8	3348-3355	history	_
26-9	3356-3358	of	_
26-10	3359-3364	other	_
26-11	3365-3376	psychiatric	_
26-12	3377-3386	disorders	_
26-13	3387-3390	and	_
26-14	3391-3397	severe	_
26-15	3398-3403	brain	_
26-16	3404-3410	injury	_
26-17	3411-3412	(	_
26-18	3413-3416	any	_
26-19	3417-3423	closed	_
26-20	3424-3426	or	_
26-21	3427-3431	open	_
26-22	3432-3440	injuries	_
26-23	3441-3445	that	_
26-24	3446-3449	may	_
26-25	3450-3452	be	_
26-26	3453-3460	related	_
26-27	3461-3463	to	_
26-28	3464-3471	current	_
26-29	3472-3480	symptoms	_
26-30	3481-3483	or	_
26-31	3484-3493	cognitive	_
26-32	3494-3503	functions	_
26-33	3504-3505	)	_
26-34	3506-3507	,	_
26-35	3508-3515	current	_
26-36	3516-3525	substance	_
26-37	3526-3531	abuse	_
26-38	3532-3533	,	_
26-39	3534-3537	and	_
26-40	3538-3547	currently	_
26-41	3548-3554	having	_
26-42	3555-3560	acute	_
26-43	3561-3570	psychotic	_
26-44	3571-3579	episodes	_
26-45	3580-3581	.	_

27-1	3582-3585	The	_
27-2	3586-3593	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
27-3	3594-3602	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
27-4	3603-3607	were	_
27-5	3608-3617	recruited	_
27-6	3618-3622	from	_
27-7	3623-3626	the	_
27-8	3627-3631	same	_
27-9	3632-3644	geographical	_
27-10	3645-3651	region	_
27-11	3652-3654	as	_
27-12	3655-3658	the	_
27-13	3659-3667	patients	_
27-14	3668-3670	by	_
27-15	3671-3684	advertisement	_
27-16	3685-3688	and	_
27-17	3689-3697	received	_
27-18	3698-3710	unstructured	_
27-19	3711-3719	clinical	_
27-20	3720-3729	interview	_
27-21	3730-3732	by	_
27-22	3733-3744	experienced	_
27-23	3745-3758	psychiatrists	_
27-24	3759-3761	to	_
27-25	3762-3768	screen	_
27-26	3769-3772	for	_
27-27	3773-3776	any	_
27-28	3777-3785	personal	_
27-29	3786-3788	or	_
27-30	3789-3795	family	_
27-31	3796-3803	history	_
27-32	3804-3806	of	_
27-33	3807-3818	psychiatric	_
27-34	3819-3828	disorders	_
27-35	3829-3830	.	_

28-1	3831-3835	Most	_
28-2	3836-3843	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
28-3	3844-3852	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
28-4	3853-3857	were	_
28-5	3858-3866	involved	_
28-6	3867-3869	in	_
28-7	3870-3873	our	_
28-8	3874-3882	previous	_
28-9	3883-3890	studies	_
28-10	3891-3892	.	_

29-1	3893-3896	All	_
29-2	3897-3905	patients	_
29-3	3906-3909	and	_
29-4	3910-3918	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-5	3919-3922	had	_
29-6	3923-3929	normal	_
29-7	3930-3932	or	_
29-8	3933-3952	corrected-to-normal	_
29-9	3953-3959	vision	_
29-10	3960-3963	and	_
29-11	3964-3968	were	_
29-12	3969-3981	right-handed	_
29-13	3982-3984	as	_
29-14	3985-3993	assessed	_
29-15	3994-3996	by	_
29-16	3997-4000	the	_
29-17	4001-4010	Edinburgh	_
29-18	4011-4021	handedness	_
29-19	4022-4031	inventory	_
29-20	4032-4033	.	_

30-1	4034-4038	None	_
30-2	4039-4041	of	_
30-3	4042-4045	the	_
30-4	4046-4054	patients	_
30-5	4055-4058	and	_
30-6	4059-4067	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
30-7	4068-4076	reported	_
30-8	4077-4080	any	_
30-9	4081-4088	history	_
30-10	4089-4091	of	_
30-11	4092-4096	hard	_
30-12	4097-4101	drug	_
30-13	4102-4105	use	_
30-14	4106-4107	(	_
30-15	4108-4112	e.g.	_
30-16	4113-4114	,	_
30-17	4115-4122	cocaine	_
30-18	4123-4124	,	_
30-19	4125-4130	crack	_
30-20	4131-4132	,	_
30-21	4133-4139	heroin	_
30-22	4140-4141	,	_
30-23	4142-4157	methamphetamine	_
30-24	4158-4159	,	_
30-25	4160-4163	etc	_
30-26	4164-4165	.	_
30-27	4166-4167	)	_
30-28	4168-4169	.	_

31-1	4170-4180	Additional	_
31-2	4181-4192	demographic	_
31-3	4193-4196	and	_
31-4	4197-4205	clinical	_
31-5	4206-4217	information	_
31-6	4218-4221	for	_
31-7	4222-4226	both	_
31-8	4227-4235	patients	_
31-9	4236-4239	and	_
31-10	4240-4248	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-11	4249-4251	is	_
31-12	4252-4257	shown	_
31-13	4258-4260	in	_
31-14	4261-4266	Table	_
31-15	4267-4268	1	_
31-16	4269-4270	.	_

32-1	4271-4275	This	_
32-2	4276-4281	study	_
32-3	4282-4284	's	_
32-4	4285-4293	protocol	_
32-5	4294-4297	was	_
32-6	4298-4306	reviewed	_
32-7	4307-4310	and	_
32-8	4311-4319	approved	_
32-9	4320-4322	by	_
32-10	4323-4326	the	_
32-11	4327-4340	Institutional	_
32-12	4341-4347	Review	_
32-13	4348-4353	Board	_
32-14	4354-4356	of	_
32-15	4357-4360	the	_
32-16	4361-4370	Institute	_
32-17	4371-4373	of	_
32-18	4374-4383	Cognitive	_
32-19	4384-4396	Neuroscience	_
32-20	4397-4400	and	_
32-21	4401-4409	Learning	_
32-22	4410-4412	at	_
32-23	4413-4420	Beijing	_
32-24	4421-4427	Normal	_
32-25	4428-4438	University	_
32-26	4439-4440	.	_

33-1	4441-4445	This	_
33-2	4446-4451	study	_
33-3	4452-4455	was	_
33-4	4456-4465	conducted	_
33-5	4466-4468	in	_
33-6	4469-4479	accordance	_
33-7	4480-4484	with	_
33-8	4485-4488	the	_
33-9	4489-4497	approved	_
33-10	4498-4506	protocol	_
33-11	4507-4508	.	_

34-1	4509-4512	All	_
34-2	4513-4525	participants	_
34-3	4526-4530	were	_
34-4	4531-4534	Han	_
34-5	4535-4542	Chinese	_
34-6	4543-4546	and	_
34-7	4547-4551	gave	_
34-8	4552-4559	written	_
34-9	4560-4568	informed	_
34-10	4569-4576	consent	_
34-11	4577-4580	for	_
34-12	4581-4585	this	_
34-13	4586-4591	study	_
34-14	4592-4593	.	_

35-1	4594-4604	Genotyping	_
35-2	4605-4612	Genomic	_
35-3	4613-4616	DNA	_
35-4	4617-4620	was	_
35-5	4621-4630	extracted	_
35-6	4631-4636	using	_
35-7	4637-4640	the	_
35-8	4641-4649	standard	_
35-9	4650-4656	method	_
35-10	4657-4658	.	_

36-1	4659-4662	The	_
36-2	4663-4666	SNP	_
36-3	4667-4676	rs1344706	_
36-4	4677-4680	was	_
36-5	4681-4690	genotyped	_
36-6	4691-4696	using	_
36-7	4697-4703	TaqMan	_
36-8	4704-4719	allele-specific	_
36-9	4720-4726	assays	_
36-10	4727-4729	on	_
36-11	4730-4733	the	_
36-12	4734-4740	7900HT	_
36-13	4741-4745	Fast	_
36-14	4746-4755	Real-Time	_
36-15	4756-4759	PCR	_
36-16	4760-4766	System	_
36-17	4767-4768	(	_
36-18	4769-4776	Applied	_
36-19	4777-4787	Biosystems	_
36-20	4788-4789	,	_
36-21	4790-4796	Foster	_
36-22	4797-4801	City	_
36-23	4802-4803	,	_
36-24	4804-4806	CA	_
36-25	4807-4808	,	_
36-26	4809-4815	U.S.A.	_
36-27	4816-4817	)	_
36-28	4818-4819	.	_

37-1	4820-4823	The	_
37-2	4824-4830	sample	_
37-3	4831-4838	success	_
37-4	4839-4843	rate	_
37-5	4844-4847	was	_
37-6	4848-4851	100	_
37-7	4852-4853	%	_
37-8	4854-4855	.	_

38-1	4856-4859	The	_
38-2	4860-4875	reproducibility	_
38-3	4876-4878	of	_
38-4	4879-4882	the	_
38-5	4883-4893	genotyping	_
38-6	4894-4897	was	_
38-7	4898-4901	100	_
38-8	4902-4903	%	_
38-9	4904-4909	based	_
38-10	4910-4912	on	_
38-11	4913-4914	a	_
38-12	4915-4924	duplicate	_
38-13	4925-4933	analysis	_
38-14	4934-4936	of	_
38-15	4937-4939	40	_
38-16	4940-4941	%	_
38-17	4942-4944	of	_
38-18	4945-4948	the	_
38-19	4949-4958	genotypes	_
38-20	4959-4960	.	_

39-1	4961-4968	Imaging	_
39-2	4969-4973	data	_
39-3	4974-4985	acquisition	_
39-4	4986-4989	All	_
39-5	4990-4997	imaging	_
39-6	4998-5002	data	_
39-7	5003-5007	were	_
39-8	5008-5016	acquired	_
39-9	5017-5019	at	_
39-10	5020-5023	the	_
39-11	5024-5029	Brain	_
39-12	5030-5037	Imaging	_
39-13	5038-5044	Center	_
39-14	5045-5047	of	_
39-15	5048-5055	Beijing	_
39-16	5056-5062	Normal	_
39-17	5063-5073	University	_
39-18	5074-5075	.	_

40-1	5076-5079	All	_
40-2	5080-5092	participants	_
40-3	5093-5097	were	_
40-4	5098-5105	scanned	_
40-5	5106-5108	on	_
40-6	5109-5110	a	_
40-7	5111-5118	Siemens	_
40-8	5119-5120	3	http://maven.renci.org/NeuroBridge/neurobridge#2Level
40-9	5121-5122	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
40-10	5123-5130	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
40-11	5131-5132	(	_
40-12	5133-5140	Siemens	_
40-13	5141-5142	,	_
40-14	5143-5151	Erlangen	_
40-15	5152-5153	,	_
40-16	5154-5161	Germany	_
40-17	5162-5163	)	_
40-18	5164-5168	with	_
40-19	5169-5174	their	_
40-20	5175-5179	head	_
40-21	5180-5186	snugly	_
40-22	5187-5192	fixed	_
40-23	5193-5197	with	_
40-24	5198-5204	straps	_
40-25	5205-5208	and	_
40-26	5209-5213	foam	_
40-27	5214-5218	pads	_
40-28	5219-5221	to	_
40-29	5222-5230	restrict	_
40-30	5231-5235	head	_
40-31	5236-5244	movement	_
40-32	5245-5246	.	_

41-1	5247-5260	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
41-2	5261-5267	images	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
41-3	5268-5269	(	_
41-4	5270-5273	240	_
41-5	5274-5281	volumes	_
41-6	5282-5283	)	_
41-7	5284-5288	were	_
41-8	5289-5297	acquired	_
41-9	5298-5303	first	_
41-10	5304-5305	,	_
41-11	5306-5314	followed	_
41-12	5315-5317	by	_
41-13	5318-5321	the	_
41-14	5322-5324	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-15	5325-5329	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-16	5330-5331	.	_

42-1	5332-5338	During	_
42-2	5339-5342	the	_
42-3	5343-5356	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-4	5357-5361	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-5	5362-5366	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-6	5367-5377	collection	_
42-7	5378-5379	(	_
42-8	5380-5387	lasting	_
42-9	5388-5393	about	_
42-10	5394-5395	8	_
42-11	5396-5399	min	_
42-12	5400-5401	)	_
42-13	5402-5403	,	_
42-14	5404-5407	all	_
42-15	5408-5416	subjects	_
42-16	5417-5421	were	_
42-17	5422-5430	required	_
42-18	5431-5433	to	_
42-19	5434-5438	keep	_
42-20	5439-5444	their	_
42-21	5445-5449	eyes	_
42-22	5450-5456	closed	_
42-23	5457-5458	,	_
42-24	5459-5461	to	_
42-25	5462-5466	stay	_
42-26	5467-5472	still	_
42-27	5473-5476	but	_
42-28	5477-5484	relaxed	_
42-29	5485-5486	,	_
42-30	5487-5490	and	_
42-31	5491-5494	not	_
42-32	5495-5497	to	_
42-33	5498-5503	think	_
42-34	5504-5506	of	_
42-35	5507-5515	anything	_
42-36	5516-5518	in	_
42-37	5519-5529	particular	_
42-38	5530-5533	and	_
42-39	5534-5537	not	_
42-40	5538-5540	to	_
42-41	5541-5545	fall	_
42-42	5546-5552	asleep	_
42-43	5553-5554	.	_

43-1	5555-5558	The	_
43-2	5559-5572	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
43-3	5573-5579	images	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
43-4	5580-5584	were	_
43-5	5585-5594	collected	_
43-6	5595-5602	axially	_
43-7	5603-5608	using	_
43-8	5609-5620	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-9	5621-5628	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-10	5629-5630	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-11	5631-5634	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-12	5635-5636	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-13	5637-5645	sequence	_
43-14	5646-5647	:	_
43-15	5648-5658	repetition	_
43-16	5659-5663	time	_
43-17	5664-5665	(	_
43-18	5666-5668	TR	_
43-19	5669-5670	)	_
43-20	5671-5672	=	_
43-21	5673-5677	2000	_
43-22	5678-5680	ms	_
43-23	5681-5682	;	_
43-24	5683-5687	echo	_
43-25	5688-5692	time	_
43-26	5693-5694	(	_
43-27	5695-5697	TE	_
43-28	5698-5699	)	_
43-29	5700-5701	=	_
43-30	5702-5704	30	_
43-31	5705-5707	ms	_
43-32	5708-5709	;	_
43-33	5710-5714	flip	_
43-34	5715-5720	angle	_
43-35	5721-5722	(	_
43-36	5723-5725	FA	_
43-37	5726-5727	)	_
43-38	5728-5729	=	_
43-39	5730-5733	90°	_
43-40	5734-5735	;	_
43-41	5736-5741	field	_
43-42	5742-5744	of	_
43-43	5745-5749	view	_
43-44	5750-5751	(	_
43-45	5752-5755	FOV	_
43-46	5756-5757	)	_
43-47	5758-5759	=	_
43-48	5760-5763	200	_
43-49	5764-5765	×	_
43-50	5766-5769	200	_
43-51	5770-5773	mm2	_
43-52	5774-5775	;	_
43-53	5776-5782	matrix	_
43-54	5783-5787	size	_
43-55	5788-5789	=	_
43-56	5790-5792	64	_
43-57	5793-5794	×	_
43-58	5795-5797	64	_
43-59	5798-5799	;	_
43-60	5800-5805	axial	_
43-61	5806-5812	slices	_
43-62	5813-5814	=	_
43-63	5815-5817	31	_
43-64	5818-5819	;	_
43-65	5820-5823	4.0	_
43-66	5824-5826	mm	_
43-67	5827-5832	slice	_
43-68	5833-5842	thickness	_
43-69	5843-5850	without	_
43-70	5851-5854	gap	_
43-71	5855-5856	;	_
43-72	5857-5862	voxel	_
43-73	5863-5867	size	_
43-74	5868-5869	=	_
43-75	5870-5875	3.125	_
43-76	5876-5877	×	_
43-77	5878-5883	3.125	_
43-78	5884-5885	×	_
43-79	5886-5889	4.0	_
43-80	5890-5893	mm3	_
43-81	5894-5895	.	_

44-1	5896-5906	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
44-2	5907-5913	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
44-3	5914-5918	were	_
44-4	5919-5927	acquired	_
44-5	5928-5933	using	_
44-6	5934-5935	a	_
44-7	5936-5947	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-8	5948-5956	sagittal	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-9	5957-5959	3D	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-10	5960-5982	magnetization-prepared	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-11	5983-5988	rapid	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-12	5989-5997	gradient	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-13	5998-6002	echo	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-14	6003-6004	(	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-15	6005-6011	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-16	6012-6013	)	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
44-17	6014-6022	sequence	_
44-18	6023-6024	:	_
44-19	6025-6027	TR	_
44-20	6028-6029	=	_
44-21	6030-6034	2530	_
44-22	6035-6037	ms	_
44-23	6038-6039	;	_
44-24	6040-6042	TE	_
44-25	6043-6044	=	_
44-26	6045-6049	3.45	_
44-27	6050-6052	ms	_
44-28	6053-6054	;	_
44-29	6055-6057	FA	_
44-30	6058-6059	=	_
44-31	6060-6062	7o	_
44-32	6063-6064	;	_
44-33	6065-6068	FOV	_
44-34	6069-6070	=	_
44-35	6071-6074	256	_
44-36	6075-6076	×	_
44-37	6077-6080	256	_
44-38	6081-6084	mm2	_
44-39	6085-6086	;	_
44-40	6087-6093	matrix	_
44-41	6094-6098	size	_
44-42	6099-6100	=	_
44-43	6101-6104	256	_
44-44	6105-6106	×	_
44-45	6107-6110	256	_
44-46	6111-6112	;	_
44-47	6113-6119	slices	_
44-48	6120-6121	=	_
44-49	6122-6125	176	_
44-50	6126-6127	;	_
44-51	6128-6137	thickness	_
44-52	6138-6139	=	_
44-53	6140-6143	1.0	_
44-54	6144-6146	mm	_
44-55	6147-6148	;	_
44-56	6149-6154	voxel	_
44-57	6155-6159	size	_
44-58	6160-6161	=	_
44-59	6162-6163	1	_
44-60	6164-6165	×	_
44-61	6166-6167	1	_
44-62	6168-6169	×	_
44-63	6170-6171	1	_
44-64	6172-6175	mm3	_
44-65	6176-6177	.	_

45-1	6178-6182	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-2	6183-6187	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-3	6188-6201	preprocessing	_
45-4	6202-6212	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
45-5	6213-6220	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
45-6	6221-6225	data	_
45-7	6226-6230	were	_
45-8	6231-6243	preprocessed	_
45-9	6244-6247	and	_
45-10	6248-6256	analyzed	_
45-11	6257-6262	using	_
45-12	6263-6274	Statistical	_
45-13	6275-6285	Parametric	_
45-14	6286-6293	Mapping	_
45-15	6294-6295	(	_
45-16	6296-6301	SPM12	_
45-17	6302-6303	,	_
45-18	6304-6312	Wellcome	_
45-19	6313-6323	Department	_
45-20	6324-6326	of	_
45-21	6327-6336	Cognitive	_
45-22	6337-6346	Neurology	_
45-23	6347-6348	,	_
45-24	6349-6355	London	_
45-25	6356-6357	,	_
45-26	6358-6360	UK	_
45-27	6361-6362	)	_
45-28	6363-6364	.	_

46-1	6365-6378	Preprocessing	_
46-2	6379-6381	of	_
46-3	6382-6395	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-4	6396-6400	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-5	6401-6405	data	_
46-6	6406-6414	included	_
46-7	6415-6420	slice	_
46-8	6421-6427	timing	_
46-9	6428-6429	(	_
46-10	6430-6432	to	_
46-11	6433-6440	correct	_
46-12	6441-6444	the	_
46-13	6445-6456	acquisition	_
46-14	6457-6461	time	_
46-15	6462-6473	differences	_
46-16	6474-6481	between	_
46-17	6482-6488	slices	_
46-18	6489-6490	)	_
46-19	6491-6492	,	_
46-20	6493-6504	realignment	_
46-21	6505-6506	(	_
46-22	6507-6519	participants	_
46-23	6520-6524	with	_
46-24	6525-6526	>	_
46-25	6527-6528	3	_
46-26	6529-6531	mm	_
46-27	6532-6539	maximum	_
46-28	6540-6552	displacement	_
46-29	6553-6555	in	_
46-30	6556-6559	any	_
46-31	6560-6562	of	_
46-32	6563-6566	the	_
46-33	6567-6568	x	_
46-34	6569-6570	,	_
46-35	6571-6572	y	_
46-36	6573-6574	,	_
46-37	6575-6576	z	_
46-38	6577-6587	directions	_
46-39	6588-6590	or	_
46-40	6591-6592	>	_
46-41	6593-6595	3°	_
46-42	6596-6598	of	_
46-43	6599-6606	angular	_
46-44	6607-6615	rotation	_
46-45	6616-6621	about	_
46-46	6622-6625	any	_
46-47	6626-6630	axis	_
46-48	6631-6635	were	_
46-49	6636-6644	excluded	_
46-50	6645-6646	)	_
46-51	6647-6648	,	_
46-52	6649-6662	normalization	_
46-53	6663-6665	to	_
46-54	6666-6669	the	_
46-55	6670-6673	MNI	_
46-56	6674-6679	space	_
46-57	6680-6681	(	_
46-58	6682-6686	each	_
46-59	6687-6698	participant	_
46-60	6699-6701	's	_
46-61	6702-6713	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-62	6714-6720	images	_
46-63	6721-6725	were	_
46-64	6726-6731	first	_
46-65	6732-6744	coregistered	_
46-66	6745-6747	to	_
46-67	6748-6751	the	_
46-68	6752-6756	mean	_
46-69	6757-6767	functional	_
46-70	6768-6773	image	_
46-71	6774-6779	after	_
46-72	6780-6784	head	_
46-73	6785-6791	motion	_
46-74	6792-6802	correction	_
46-75	6803-6806	and	_
46-76	6807-6811	then	_
46-77	6812-6821	segmented	_
46-78	6822-6826	into	_
46-79	6827-6832	white	_
46-80	6833-6839	matter	_
46-81	6840-6841	,	_
46-82	6842-6846	grey	_
46-83	6847-6853	matter	_
46-84	6854-6855	,	_
46-85	6856-6859	and	_
46-86	6860-6873	cerebrospinal	_
46-87	6874-6879	fluid	_
46-88	6880-6881	,	_
46-89	6882-6885	and	_
46-90	6886-6895	generated	_
46-91	6896-6908	segmentation	_
46-92	6909-6919	parameters	_
46-93	6920-6924	were	_
46-94	6925-6929	then	_
46-95	6930-6934	used	_
46-96	6935-6937	to	_
46-97	6938-6947	normalize	_
46-98	6948-6958	functional	_
46-99	6959-6965	images	_
46-100	6966-6968	to	_
46-101	6969-6972	the	_
46-102	6973-6976	MNI	_
46-103	6977-6985	standard	_
46-104	6986-6991	space	_
46-105	6992-6993	)	_
46-106	6994-6995	,	_
46-107	6996-7006	resampling	_
46-108	7007-7009	to	_
46-109	7010-7015	voxel	_
46-110	7016-7020	size	_
46-111	7021-7022	3	_
46-112	7023-7024	×	_
46-113	7025-7026	3	_
46-114	7027-7028	×	_
46-115	7029-7030	3	_
46-116	7031-7034	mm3	_
46-117	7035-7036	,	_
46-118	7037-7044	spatial	_
46-119	7045-7054	smoothing	_
46-120	7055-7059	with	_
46-121	7060-7061	a	_
46-122	7062-7066	4-mm	_
46-123	7067-7071	full	_
46-124	7072-7077	width	_
46-125	7078-7080	at	_
46-126	7081-7085	half	_
46-127	7086-7093	maximum	_
46-128	7094-7095	(	_
46-129	7096-7100	FWHM	_
46-130	7101-7102	)	_
46-131	7103-7111	Gaussian	_
46-132	7112-7118	kernel	_
46-133	7119-7120	,	_
46-134	7121-7124	and	_
46-135	7125-7132	removal	_
46-136	7133-7135	of	_
46-137	7136-7142	linear	_
46-138	7143-7149	trends	_
46-139	7150-7153	and	_
46-140	7154-7162	temporal	_
46-141	7163-7169	filter	_
46-142	7170-7171	(	_
46-143	7172-7180	0.01–0.1	_
46-144	7181-7183	Hz	_
46-145	7184-7185	,	_
46-146	7186-7188	to	_
46-147	7189-7195	reduce	_
46-148	7196-7209	low-frequency	_
46-149	7210-7216	drifts	_
46-150	7217-7220	and	_
46-151	7221-7235	high-frequency	_
46-152	7236-7249	physiological	_
46-153	7250-7255	noise	_
46-154	7256-7257	)	_
46-155	7258-7259	.	_

47-1	7260-7262	To	_
47-2	7263-7270	further	_
47-3	7271-7277	reduce	_
47-4	7278-7281	the	_
47-5	7282-7289	effects	_
47-6	7290-7292	of	_
47-7	7293-7304	confounding	_
47-8	7305-7312	factors	_
47-9	7313-7314	,	_
47-10	7315-7316	6	_
47-11	7317-7321	head	_
47-12	7322-7328	motion	_
47-13	7329-7339	parameters	_
47-14	7340-7343	and	_
47-15	7344-7349	white	_
47-16	7350-7356	matter	_
47-17	7357-7360	and	_
47-18	7361-7374	cerebrospinal	_
47-19	7375-7380	fluid	_
47-20	7381-7388	signals	_
47-21	7389-7393	were	_
47-22	7394-7402	included	_
47-23	7403-7405	as	_
47-24	7406-7416	covariates	_
47-25	7417-7418	.	_

48-1	7419-7422	The	_
48-2	7423-7429	global	_
48-3	7430-7434	mean	_
48-4	7435-7441	signal	_
48-5	7442-7445	was	_
48-6	7446-7449	not	_
48-7	7450-7458	included	_
48-8	7459-7461	as	_
48-9	7462-7463	a	_
48-10	7464-7473	covariate	_
48-11	7474-7475	.	_

49-1	7476-7482	Degree	_
49-2	7483-7493	centrality	_
49-3	7494-7502	analysis	_
49-4	7503-7509	Degree	_
49-5	7510-7520	centrality	_
49-6	7521-7522	(	_
49-7	7523-7534	whole-range	_
49-8	7535-7536	)	_
49-9	7537-7539	is	_
49-10	7540-7541	a	_
49-11	7542-7549	measure	_
49-12	7550-7552	in	_
49-13	7553-7558	graph	_
49-14	7559-7565	theory	_
49-15	7566-7570	that	_
49-16	7571-7580	estimates	_
49-17	7581-7584	the	_
49-18	7585-7590	total	_
49-19	7591-7603	connectivity	_
49-20	7604-7611	between	_
49-21	7612-7613	a	_
49-22	7614-7619	voxel	_
49-23	7620-7623	and	_
49-24	7624-7627	the	_
49-25	7628-7632	rest	_
49-26	7633-7635	of	_
49-27	7636-7639	the	_
49-28	7640-7645	brain	_
49-29	7646-7647	.	_

50-1	7648-7650	It	_
50-2	7651-7654	has	_
50-3	7655-7660	often	_
50-4	7661-7665	been	_
50-5	7666-7670	used	_
50-6	7671-7673	to	_
50-7	7674-7682	identify	_
50-8	7683-7686	the	_
50-9	7687-7690	hub	_
50-10	7691-7698	regions	_
50-11	7699-7701	of	_
50-12	7702-7705	the	_
50-13	7706-7711	brain	_
50-14	7712-7719	network	_
50-15	7720-7721	.	_

51-1	7722-7734	Specifically	_
51-2	7735-7736	,	_
51-3	7737-7744	Pearson	_
51-4	7745-7747	's	_
51-5	7748-7759	correlation	_
51-6	7760-7772	coefficients	_
51-7	7773-7777	were	_
51-8	7778-7786	computed	_
51-9	7787-7789	in	_
51-10	7790-7793	all	_
51-11	7794-7802	possible	_
51-12	7803-7808	pairs	_
51-13	7809-7811	of	_
51-14	7812-7818	voxels	_
51-15	7819-7820	,	_
51-16	7821-7826	which	_
51-17	7827-7835	resulted	_
51-18	7836-7838	in	_
51-19	7839-7840	a	_
51-20	7841-7852	whole-brain	_
51-21	7853-7863	functional	_
51-22	7864-7876	connectivity	_
51-23	7877-7883	matrix	_
51-24	7884-7885	.	_

52-1	7886-7890	This	_
52-2	7891-7895	step	_
52-3	7896-7899	was	_
52-4	7900-7910	restricted	_
52-5	7911-7913	to	_
52-6	7914-7915	a	_
52-7	7916-7926	predefined	_
52-8	7927-7931	grey	_
52-9	7932-7938	matter	_
52-10	7939-7943	mask	_
52-11	7944-7948	that	_
52-12	7949-7952	was	_
52-13	7953-7956	the	_
52-14	7957-7961	same	_
52-15	7962-7964	as	_
52-16	7965-7967	in	_
52-17	7968-7976	previous	_
52-18	7977-7984	studies	_
52-19	7985-7986	.	_

53-1	7987-7990	For	_
53-2	7991-7992	a	_
53-3	7993-7998	given	_
53-4	7999-8004	voxel	_
53-5	8005-8006	,	_
53-6	8007-8010	its	_
53-7	8011-8017	degree	_
53-8	8018-8028	centrality	_
53-9	8029-8032	was	_
53-10	8033-8043	calculated	_
53-11	8044-8049	using	_
53-12	8050-8053	the	_
53-13	8054-8063	following	_
53-14	8064-8072	equation	_
53-15	8073-8074	:	_
53-16	8075-8080	where	_
53-17	8081-8084	rij	_
53-18	8085-8088	was	_
53-19	8089-8096	Pearson	_
53-20	8097-8099	's	_
53-21	8100-8111	correlation	_
53-22	8112-8123	coefficient	_
53-23	8124-8131	between	_
53-24	8132-8137	voxel	_
53-25	8138-8139	i	_
53-26	8140-8143	and	_
53-27	8144-8149	voxel	_
53-28	8150-8151	j	_
53-29	8152-8153	,	_
53-30	8154-8157	and	_
53-31	8158-8160	r0	_
53-32	8161-8164	was	_
53-33	8165-8166	a	_
53-34	8167-8178	correlation	_
53-35	8179-8188	threshold	_
53-36	8189-8193	that	_
53-37	8194-8197	was	_
53-38	8198-8202	used	_
53-39	8203-8205	to	_
53-40	8206-8215	eliminate	_
53-41	8216-8224	possible	_
53-42	8225-8233	spurious	_
53-43	8234-8246	correlations	_
53-44	8247-8254	arising	_
53-45	8255-8259	from	_
53-46	8260-8265	noise	_
53-47	8266-8267	.	_

54-1	8268-8270	In	_
54-2	8271-8274	the	_
54-3	8275-8282	current	_
54-4	8283-8288	study	_
54-5	8289-8290	,	_
54-6	8291-8293	r0	_
54-7	8294-8295	=	_
54-8	8296-8299	0.2	_
54-9	8300-8301	.	_

55-1	8302-8304	It	_
55-2	8305-8307	is	_
55-3	8308-8313	worth	_
55-4	8314-8320	noting	_
55-5	8321-8325	that	_
55-6	8326-8335	different	_
55-7	8336-8347	correlation	_
55-8	8348-8358	thresholds	_
55-9	8359-8362	did	_
55-10	8363-8366	not	_
55-11	8367-8373	change	_
55-12	8374-8377	the	_
55-13	8378-8388	connection	_
55-14	8389-8396	pattern	_
55-15	8397-8410	significantly	_
55-16	8411-8412	,	_
55-17	8413-8418	which	_
55-18	8419-8421	is	_
55-19	8422-8432	consistent	_
55-20	8433-8437	with	_
55-21	8438-8446	previous	_
55-22	8447-8454	reports	_
55-23	8455-8456	.	_

56-1	8457-8458	A	_
56-2	8459-8465	degree	_
56-3	8466-8476	centrality	_
56-4	8477-8480	map	_
56-5	8481-8484	for	_
56-6	8485-8489	each	_
56-7	8490-8500	individual	_
56-8	8501-8504	was	_
56-9	8505-8513	produced	_
56-10	8514-8517	and	_
56-11	8518-8522	then	_
56-12	8523-8535	standardized	_
56-13	8536-8538	to	_
56-14	8539-8540	a	_
56-15	8541-8548	z-score	_
56-16	8549-8552	map	_
56-17	8553-8554	.	_

57-1	8555-8561	Degree	_
57-2	8562-8572	centrality	_
57-3	8573-8576	can	_
57-4	8577-8579	be	_
57-5	8580-8588	affected	_
57-6	8589-8591	by	_
57-7	8592-8604	connectivity	_
57-8	8605-8613	distance	_
57-9	8614-8621	between	_
57-10	8622-8629	regions	_
57-11	8630-8631	.	_

58-1	8632-8641	Therefore	_
58-2	8642-8643	,	_
58-3	8644-8647	for	_
58-4	8648-8655	further	_
58-5	8656-8664	analysis	_
58-6	8665-8666	,	_
58-7	8667-8669	we	_
58-8	8670-8680	subdivided	_
58-9	8681-8684	the	_
58-10	8685-8696	connections	_
58-11	8697-8700	and	_
58-12	8701-8711	associated	_
58-13	8712-8718	degree	_
58-14	8719-8729	centrality	_
58-15	8730-8737	between	_
58-16	8738-8741	all	_
58-17	8742-8750	possible	_
58-18	8751-8756	pairs	_
58-19	8757-8759	of	_
58-20	8760-8766	voxels	_
58-21	8767-8771	into	_
58-22	8772-8782	long-range	_
58-23	8783-8784	(	_
58-24	8785-8786	>	_
58-25	8787-8789	75	_
58-26	8790-8792	mm	_
58-27	8793-8794	)	_
58-28	8795-8798	and	_
58-29	8799-8810	short-range	_
58-30	8811-8812	(	_
58-31	8813-8814	<	_
58-32	8815-8817	75	_
58-33	8818-8820	mm	_
58-34	8821-8822	)	_
58-35	8823-8832	according	_
58-36	8833-8835	to	_
58-37	8836-8841	their	_
58-38	8842-8852	anatomical	_
58-39	8853-8861	distance	_
58-40	8862-8864	by	_
58-41	8865-8870	using	_
58-42	8871-8874	the	_
58-43	8875-8880	GRaph	_
58-44	8881-8892	thEoreTical	_
58-45	8893-8900	Network	_
58-46	8901-8909	Analysis	_
58-47	8910-8911	(	_
58-48	8912-8918	GRETNA	_
58-49	8919-8920	)	_
58-50	8921-8928	toolbox	_
58-51	8929-8930	.	_

59-1	8931-8942	Statistical	_
59-2	8943-8951	analysis	_
59-3	8952-8954	We	_
59-4	8955-8958	did	_
59-5	8959-8963	full	_
59-6	8964-8973	factorial	_
59-7	8974-8981	two-way	_
59-8	8982-8987	ANOVA	_
59-9	8988-8994	across	_
59-10	8995-8998	the	_
59-11	8999-9004	whole	_
59-12	9005-9010	brain	_
59-13	9011-9013	to	_
59-14	9014-9018	test	_
59-15	9019-9022	the	_
59-16	9023-9031	genotype	_
59-17	9032-9038	effect	_
59-18	9039-9040	,	_
59-19	9041-9044	the	_
59-20	9045-9054	diagnosis	_
59-21	9055-9061	effect	_
59-22	9062-9063	,	_
59-23	9064-9067	and	_
59-24	9068-9073	their	_
59-25	9074-9085	interaction	_
59-26	9086-9087	,	_
59-27	9088-9092	with	_
59-28	9093-9101	genotype	_
59-29	9102-9103	(	_
59-30	9104-9106	AA	_
59-31	9107-9110	vs.	_
59-32	9111-9116	CA/CC	_
59-33	9117-9118	)	_
59-34	9119-9122	and	_
59-35	9123-9132	diagnosis	_
59-36	9133-9134	(	_
59-37	9135-9148	schizophrenia	_
59-38	9149-9152	vs.	_
59-39	9153-9161	controls	_
59-40	9162-9163	)	_
59-41	9164-9166	as	_
59-42	9167-9172	fixed	_
59-43	9173-9180	factors	_
59-44	9181-9182	.	_

60-1	9183-9185	If	_
60-2	9186-9197	significant	_
60-3	9198-9202	main	_
60-4	9203-9210	effects	_
60-5	9211-9213	of	_
60-6	9214-9222	genotype	_
60-7	9223-9225	or	_
60-8	9226-9237	significant	_
60-9	9238-9249	interaction	_
60-10	9250-9257	effects	_
60-11	9258-9260	of	_
60-12	9261-9269	genotype	_
60-13	9270-9271	×	_
60-14	9272-9281	diagnosis	_
60-15	9282-9286	were	_
60-16	9287-9292	found	_
60-17	9293-9294	,	_
60-18	9295-9303	genotype	_
60-19	9304-9311	effects	_
60-20	9312-9316	were	_
60-21	9317-9324	further	_
60-22	9325-9333	explored	_
60-23	9334-9339	using	_
60-24	9340-9350	two-sample	_
60-25	9351-9357	t-test	_
60-26	9358-9364	across	_
60-27	9365-9368	the	_
60-28	9369-9374	whole	_
60-29	9375-9380	brain	_
60-30	9381-9383	in	_
60-31	9384-9387	the	_
60-32	9388-9396	patients	_
60-33	9397-9400	and	_
60-34	9401-9409	controls	_
60-35	9410-9420	separately	_
60-36	9421-9422	.	_

61-1	9423-9425	To	_
61-2	9426-9433	correct	_
61-3	9434-9437	for	_
61-4	9438-9446	multiple	_
61-5	9447-9458	comparisons	_
61-6	9459-9460	,	_
61-7	9461-9473	significance	_
61-8	9474-9477	was	_
61-9	9478-9488	determined	_
61-10	9489-9494	using	_
61-11	9495-9496	a	_
61-12	9497-9508	voxel-level	_
61-13	9509-9518	threshold	_
61-14	9519-9521	of	_
61-15	9522-9523	P	_
61-16	9524-9525	<	_
61-17	9526-9531	0.001	_
61-18	9532-9535	and	_
61-19	9536-9549	cluster-level	_
61-20	9550-9561	family-wise	_
61-21	9562-9567	error	_
61-22	9568-9569	(	_
61-23	9570-9573	FWE	_
61-24	9574-9575	)	_
61-25	9576-9585	corrected	_
61-26	9586-9587	P	_
61-27	9588-9589	<	_
61-28	9590-9594	0.05	_
61-29	9595-9596	.	_

